Adam Lyko, MD
Endocrinology, Diabetes & Metabolism · Post Falls, IDNPI 1659485332
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), speaking fees and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 48.7% of the total.
Across 53 payments — averaging $98.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$3K
- Novo Nordisk$486
- BETA Bionics, Inc.$382
- Ascendis Pharma Endocrinology Inc$333
- Amgen$307
- Medtronic$285
- plus $895 from 8 others
What the payments were for
- Speaking & faculty fees$2,25043%
- Food & beverage$2,86055%
- Education$1292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 12 | $2,550 |
| Novo Nordisk | 10 | $486 |
| BETA Bionics, Inc. | 3 | $382 |
| Ascendis Pharma Endocrinology Inc | 5 | $333 |
| Amgen | 4 | $307 |
| Medtronic | 3 | $285 |
| Sequel Med Tech, LLC | 2 | $231 |
| Insulet Corporation | 5 | $150 |
| AstraZeneca | 3 | $147 |
| Shire North American Group Inc | 1 | $125 |
| Radius Health, Inc. | 2 | $115 |
| Kyowa Kirin, Inc. | 1 | $60 |
| Dexcom, Inc. | 1 | $44 |
| Abbott | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 149 | $241,030 |
| IsturisaOsilodrostat Phosphate | 14 | $172,926 |
| JardianceEmpagliflozin | 89 | $102,756 |
| MounjaroTirzepatide | 90 | $100,305 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 81 | $93,986 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 41 | $46,902 |
| Tresiba Flextouch U-100Insulin Degludec | 72 | $40,268 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $30,864 |
| TrulicityDulaglutide | 16 | $30,535 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $29,924 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $27,626 |
| FarxigaDapagliflozin Propanediol | 23 | $23,682 |
| LyumjevInsulin Lispro-Aabc | 14 | $18,165 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $17,903 |
| XyostedTestosterone Enanthate | 27 | $16,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $486 | $246,493171 claims |
| AstraZenecaFarxiga | $147 | $23,68223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Post Falls
- Tanya BlatyPost Falls$1K
- Robert EnnisMeridian$69K
- Theodore RooseveltBoise$65K
- David LiljenquistIdaho Falls$9K
- Julie FooteBoise$8K
- Katy ConnleyEagle$6K
- Shanaz SikderBoise$3K
- Angelo CapricchioneBlackfoot$2K
- Michael HolyoakMeridian$2K
- Richard ChristensenBoise$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.